{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:48:50Z","timestamp":1761630530271},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.eimc.2008.11.002","type":"journal-article","created":{"date-parts":[[2009,9,23]],"date-time":"2009-09-23T21:01:54Z","timestamp":1253739714000},"page":"222-235","source":"Crossref","is-referenced-by-count":41,"title":["Recomendaciones de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n febrero de 2009)"],"prefix":"10.1016","volume":"27","author":[{"given":"Panel","family":"de expertos de Gesida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Plan","family":"Nacional sobre el Sida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2008.11.002_bib1","unstructured":"Panel de expertos de Gesida y Plan Nacional sobre el Sida. Recomendaciones de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana [actualizado Ene 2008; citado 31 Dic 2008]. Disponible en: http:\/\/www.gesida.seimc.org\/"},{"key":"10.1016\/j.eimc.2008.11.002_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2008.11.002_bib3","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-128 [citado 31 Dic 2008]. Disponible en: www.AIDSinfo.nih.gov."},{"key":"10.1016\/j.eimc.2008.11.002_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1157\/13096750","article-title":"Recomendaciones de Gesida\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualizaci\u00f3n, enero de 2007)","volume":"25","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2008.11.002_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkm516","article-title":"Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome","volume":"61","author":"Garcia-Gasco","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2008.11.002_bib6","first-page":"62","article-title":"Update of the Drug Resistance Mutations in HIV-1: Spring 2008","volume":"16","author":"Johnson","year":"2008","journal-title":"Top HIV Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1157\/13108707","article-title":"Resistencias primarias a los f\u00e1rmacos antirretrovirales en los pacientes diagnosticados de infecci\u00f3n por el VIH en Gran Canaria entre los a\u00f1os 2002\u20132005","volume":"25","author":"S\u00e1nchez O\u00f1oro","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2008.11.002_bib8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1097\/QAD.0b013e3283034953","article-title":"Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy","volume":"22","author":"Peuchant","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2008.11.002_bib9","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1K522","article-title":"Abacavir hypersensitivity reaction: an update","volume":"42","author":"Hughes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eimc.2008.11.002_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/511035","article-title":"HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211","volume":"44","author":"Wilkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2008.11.002_bib13","unstructured":"Reeves J, Han D, Wilkin T, Wrin T, Kuritzkes DR, Petropoulos C, et al. Enhanced Version of the Trofile HIV Co-receptor Tropism Assay Predicts Emergence of CXCR4 Use in ACTG5211 Vicriviroc Trial Samples. 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, Massachusetts [resumen 869]."},{"key":"10.1016\/j.eimc.2008.11.002_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1157\/13069207","article-title":"Avances en el diagn\u00f3stico y tratamiento de la infecci\u00f3n aguda por el VIH-1","volume":"22","author":"Miro","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2008.11.002_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/QCO.0b013e3282f428bf","article-title":"Primary HIV infection: to treat or not to treat?","volume":"21","author":"Fidler","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.eimc.2008.11.002_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.7326\/0003-4819-146-2-200701160-00003","article-title":"Survival of persons with and without HIV infection in Denmark, 1995\u20132005","volume":"146","author":"Lohse","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e318134257a","article-title":"HIV-infected adults with a CD4 cell count greater than 500cells\/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population","volume":"46","author":"Lewden","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2008.11.002_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/QAI.0b013e31815ee282","article-title":"Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain)","volume":"47","author":"Jaen","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2008.11.002_bib19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/586713","article-title":"Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study","volume":"197","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2008.11.002_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/QAD.0b013e3282f7cb76","article-title":"CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection","volume":"22","author":"Baker","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2008.11.002_bib21","unstructured":"D\u2019Arminio Monforte A, Abrams D, Pradier C, Weber R, Bonnet F, DeWit S, et al. HIV-induced immunodeficiency and risk of fatal AIDS-defining and non-AIDS defining malignancies:results from the D:A:D study. 14th Conference on retrovirus and opportunistic infections. Los Angeles, 2007 [resumen 84]."},{"key":"10.1016\/j.eimc.2008.11.002_bib22","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib23","unstructured":"Marin B, Thi\u00e9baut R, Rondeau V, Costagliola D, Dorrucci M, Bucher H, et al. Association between CD4 and HIV RNA with non AIDS-related causes of death in the era of combination antiretroviral therapy. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007 [resumen WEPEB019]."},{"key":"10.1016\/j.eimc.2008.11.002_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the risk of death after HIV seroconversion compared with mortality in the general population","volume":"300","author":"Bhaskaran","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2008.11.002_bib25","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","article-title":"Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies","volume":"21","author":"May","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2008.11.002_bib26","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.amjmed.2008.05.027","article-title":"The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy","volume":"121","author":"Bra\u00f1as","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/QAI.0b013e31804d685b","article-title":"CD4 cell counts of 800 cells\/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells\/mm3 or greater","volume":"45","author":"Gras","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2008.11.002_bib28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(07)60948-9","article-title":"Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study","volume":"370","author":"Mocroft","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2008.11.002_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/QAI.0b013e31815acacc","article-title":"Initiation of antiretroviral therapy at CD4 cell counts >\/=350 cells\/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency","volume":"47","author":"Lichtenstein","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2008.11.002_bib30","unstructured":"Pulido F, Arribas J, Moreno S, Gatell J, Vendrell B, Serrano O, et al. Similar virologic and immunologic response to efavirenz or lopinavir\/ritonavir-based HAART in a large cohort of antiretroviral-naive patients with advanced HIV infection. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, 2006 [resumen P9)."},{"key":"10.1016\/j.eimc.2008.11.002_bib31","unstructured":"Sierra Madero J, Villasis A, Mendez P, Mosqueda JL, Torres I, Gutierrez F, et al. A prospective, randomized, open label trial of efavirenz versus lopinavir\/ritonavir based HAART among antiretroviral therapy na\u00efve, HIV-infected individuals presenting for care with CD4 cell counts <200\/mm3 in Mexico. 17th International AIDS Conference; 3-8 August, 2008; Mexico DF [resumen TUAB0104]."},{"key":"10.1016\/j.eimc.2008.11.002_bib32","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJMc070207","article-title":"A comparison of three initial antiretroviral AIDS regimens","volume":"357","author":"Ribaudo","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib34","unstructured":"Smith K, Fine D, Patel P, et al. Similarity in efficacy and safety of abacavir\/lamivudine compared to tenofovir\/emtricitabine in combination with QD lopinavir\/ritonavir (LPV\/r) over 96 weeks in the HEAT study. 17th International AIDS Conference; 3\u20138 August, 2008; Mexico DF [resumen LBPE1138]."},{"key":"10.1016\/j.eimc.2008.11.002_bib35","unstructured":"Sax P, Tierney C, Collier A, et al. ACTG 5202: shorter time to virologic failure with ABC\/3TC than TDF\/FTC in treatment-naive subjects with HIV RNA >100,000. 17th International AIDS Conference; 3\u20138 August, 2008; Mexico DF [resumen THAB0303]."},{"key":"10.1016\/j.eimc.2008.11.002_bib36","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2008.11.002_bib37","unstructured":"Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumeck N, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine\/lamivudine), for the treatment of antiretroviral na\u00efve patients infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, 2007 [resumen WESS104]."},{"key":"10.1016\/j.eimc.2008.11.002_bib38","first-page":"67","article-title":"HIV-1 drug resistance mutations: an updated framework for the second decade of HAART","volume":"10","author":"Shafer","year":"2008","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2008.11.002_bib39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/QAI.0b013e31816856c5","article-title":"Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy","volume":"47","author":"Tan","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2008.11.002_bib40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2008.11.002_bib41","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/590943","article-title":"Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials","volume":"47","author":"Gupta","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2008.11.002_bib42","unstructured":"Hicks C, Cahn P, Ward D, Lazzarin A, Jelaska A, Drulak M, et al. Tripranavir\/r mantains long term virological suppression in highly treatment experienced patients \u2013Three year follow-up RESIST. 11th European Aids Conference, Madrid, 2007 [resumen P7.3\/25]."},{"key":"10.1016\/j.eimc.2008.11.002_bib43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2008.11.002_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2008.11.002_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2008.11.002_bib46","unstructured":"Cahn P, Molina JM, Towner W, Peeters M, Vingerhoets J, Beets G. 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR). 17th International AIDS Conference; 3\u20138 August, 2008; Mexico DF [resumen TUPE0047]."},{"key":"10.1016\/j.eimc.2008.11.002_bib47","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for Previously Treated Patients with R5 HIV-1 Infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib48","unstructured":"Van der Ryst E, Westby M. Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2007 [resumen H-715]."},{"key":"10.1016\/j.eimc.2008.11.002_bib49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2008.11.002_bib50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/524753","article-title":"Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency","volume":"46","author":"Kousignian","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2008.11.002_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/apc.2007.0052","article-title":"Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.eimc.2008.11.002_bib52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/QAI.0b013e31815e7251","article-title":"Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy","volume":"47","author":"Bozzette","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2008.11.002_bib53","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1742-1241.2007.01385.x","article-title":"Long-term complications of antiretroviral therapy: lipoatrophy","volume":"61","author":"Waters","year":"2007","journal-title":"Int J Clin Pract"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X08000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T04:40:19Z","timestamp":1633927219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X08000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0213005X08000293"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2008.11.002","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}